Ellis Andrea 4
4 · BridgeBio Pharma, Inc. · Filed Aug 7, 2025
Insider Transaction Report
Form 4
Ellis Andrea
Director
Transactions
- Exercise/Conversion
Common Stock
2025-08-05$16.75/sh+17,167$287,547→ 35,756 total - Sale
Common Stock
2025-08-05$49.00/sh−17,167$841,183→ 18,589 total - Exercise/Conversion
Stock Option (right to buy)
2025-08-05−17,167→ 34,334 totalExercise: $16.75Exp: 2033-06-21→ Common Stock (17,167 underlying)
Footnotes (2)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 30, 2024.
- [F2]The option vests in three annual installments from June 21, 2024 through June 21, 2026, subject to the Reporting Person's continued service on the Issuer's board of directors.